Used primarily in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, facilitating the degradation of disease-causing proteins. This makes it valuable in developing treatments for cancers such as multiple myeloma and other hematological malignancies. It is also explored in the design of PROTACs (proteolysis-targeting chimeras), where it serves as the E3 ligase recruiting moiety to induce degradation of specific target proteins. Due to its bromo and methoxy functional groups, it allows for further chemical modifications, enhancing its utility in structure-activity relationship studies and drug optimization.